Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georgia M Beasley

Showing results (61-70 of 130) with videos related to

Pageof 13
Sort By:
JAMA Surgery|October 11, 2023
Racial, Ethnic, and Gender Diversity Among Academic Surgical Leaders in the USYoshiko Iwai, Alice Yunzi L Yu, Nikki C Daniels, et al.
Annals of Surgical Oncology|April 5, 2014
Immunotherapy following regional chemotherapy treatment of advanced extremity melanomaBetty S Jiang, Georgia M Beasley, Paul J Speicher, et al.
Annals of Surgical Oncology|November 28, 2013
SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanomaYoshihiro Tokuhisa, Michael E Lidsky, Hiroaki Toshimitsu, et al.
Science Immunology|May 10, 2024
A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progressionMichael P Plebanek, Yue Xue, Y-Van Nguyen, et al.
Journal of Surgical Oncology|March 8, 2018
Does the number of sentinel lymph nodes removed affect the false negative rate for head and neck melanoma?Charles J Puza, Srirama Josyula, Alicia M Terando, et al.
The Journal of Surgical Research|January 30, 2019
The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With ImmunotherapyCharles J Puza, Elizabeth Schell Bressler, Alicia M Terando, et al.
Anticancer Research|September 4, 2020
Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced MelanomaJanice B Hu, Surya Ravichandran, Christel Rushing, et al.
Biorxiv : the Preprint Server for Biology|May 10, 2023
A SREBF2-dependent gene program drives an immunotolerant dendritic cell population during cancer progressionMichael P Plebanek, Yue Xue, Y-Van Nguyen, et al.
Annals of Surgery|July 7, 2022
Multicenter Experience with Neoadjuvant Therapy in Melanoma Highlights Heterogeneity in Contemporary PracticeKristen E Rhodin, Elizabeth M Gaughan, Vignesh Raman, et al.
Cancer|July 29, 2009
A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanomaGeorgia M Beasley, Nicole McMahon, Gretchen Sanders, et al.
Pageof 13

Showing results (61-70 of 130) with videos related to

Sort By:
Pageof 13
JAMA Surgery|October 11, 2023
Racial, Ethnic, and Gender Diversity Among Academic Surgical Leaders in the USYoshiko Iwai, Alice Yunzi L Yu, Nikki C Daniels, et al.
Annals of Surgical Oncology|April 5, 2014
Immunotherapy following regional chemotherapy treatment of advanced extremity melanomaBetty S Jiang, Georgia M Beasley, Paul J Speicher, et al.
Annals of Surgical Oncology|November 28, 2013
SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanomaYoshihiro Tokuhisa, Michael E Lidsky, Hiroaki Toshimitsu, et al.
Science Immunology|May 10, 2024
A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progressionMichael P Plebanek, Yue Xue, Y-Van Nguyen, et al.
Journal of Surgical Oncology|March 8, 2018
Does the number of sentinel lymph nodes removed affect the false negative rate for head and neck melanoma?Charles J Puza, Srirama Josyula, Alicia M Terando, et al.
The Journal of Surgical Research|January 30, 2019
The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With ImmunotherapyCharles J Puza, Elizabeth Schell Bressler, Alicia M Terando, et al.
Anticancer Research|September 4, 2020
Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced MelanomaJanice B Hu, Surya Ravichandran, Christel Rushing, et al.
Biorxiv : the Preprint Server for Biology|May 10, 2023
A SREBF2-dependent gene program drives an immunotolerant dendritic cell population during cancer progressionMichael P Plebanek, Yue Xue, Y-Van Nguyen, et al.
Annals of Surgery|July 7, 2022
Multicenter Experience with Neoadjuvant Therapy in Melanoma Highlights Heterogeneity in Contemporary PracticeKristen E Rhodin, Elizabeth M Gaughan, Vignesh Raman, et al.
Cancer|July 29, 2009
A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanomaGeorgia M Beasley, Nicole McMahon, Gretchen Sanders, et al.
Pageof 13